The startup is developing a pharmaceutical solution for patients with this disease that will help them overcome their movement problems, reducing falls.
Many Parkinson’s patients live with the fear of falling during their activities of daily living, unforeseen accidents that can lead to serious injuries. Falls are usually caused by mobility problems related to motor deficits, such as Freezing of Gait (FOG). Other symptoms include cognitive impairment, visual impairment, depression, anxiety and lack of sleep. These are serious health problems that limit the patient’s daily life and can lead to death, as 10% of falls resulting in bone fractures are fatal.
To contribute to solving this problem, the Gipuzkoa-based startup Golden Gait Biotech is developing a drug that seeks to reduce and prevent this type of falls in order to improve the health of patients. The efficacy shown by this drug in the studies carried out by the company offers very positive results, since 45% of the patients who took the drug reduced their falls.
In addition to reducing falls, the drug also demonstrates additional benefits related to improving the movements of Parkinson’s patients. “These positive results indicate that patients feel more confident while walking,” the startup says.
Other advantages offered by this drug are the possibility of improving postural stability, which enables the patient to “maintain a static position and body coordination”, while at the same time “improving DLI (an uncontrolled involuntary movement associated with levodopa (L-DOPA)», they explain.
More information at: https://goldengaitbiotech.com/
